T Wuorimaa
Overview
Explore the profile of T Wuorimaa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wuorimaa T, Kayhty H
Scand J Immunol
. 2002 Jul;
56(2):111-29.
PMID: 12121432
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and acute otitis media in children and adults worldwide. According to World Health Organization estimates, at least 1 million children...
2.
Olander R, Wuorimaa T, Kayhty H, Leroy O, Dagan R, Eskola J
Vaccine
. 2001 Oct;
20(3-4):336-41.
PMID: 11672895
We measured the tetanus and diphtheria antitoxin responses after administration of one dose of a mixed carrier (tetanus and diphtheria toxoids) 11-valent pneumococcal conjugate vaccine (PncDT) in 20 Finnish adults...
3.
Wuorimaa T, Dagan R, Vakevainen M, Bailleux F, Haikala R, Yaich M, et al.
J Infect Dis
. 2001 Oct;
184(9):1211-5.
PMID: 11598848
Finnish and Israeli infants received an 11-valent mixed-carrier pneumococcal conjugate vaccine with or without aluminum adjuvant at 2, 4, 6, and 12 months of age. The relative avidity of serotype...
4.
Wuorimaa T, Dagan R, Eskola J, JANCO J, Ahman H, Leroy O, et al.
Pediatr Infect Dis J
. 2001 Apr;
20(3):272-7.
PMID: 11303829
Background: A need to increase the serotype coverage of pneumococcal conjugate vaccines exists. The use of a single carrier protein may cause overload of the carrier and decrease the immune...
5.
Wuorimaa T, Kayhty H, Eskola J, Bloigu A, Leroy O, Surcel H
Scand J Immunol
. 2001 Apr;
53(4):422-8.
PMID: 11285124
The immunogenicity of pneumococcal polysaccharide (PS) vaccines can be improved by conjugating PS to a polypeptide carrier that alters the immune response from T-cell independent to T-cell dependent. In order...
6.
Wuorimaa T, Kayhty H, Leroy O, Eskola J
Vaccine
. 2001 Mar;
19(15-16):1863-9.
PMID: 11228355
We studied the safety and immunogenicity in healthy adults of an 11-valent pneumococcal conjugate vaccine. Capsular polysaccharides (PS) of serotypes 1, 4, 5, 7F, 9V, 19F and 23F were conjugated...
7.
Parkkali T, Kayhty H, Anttila M, Ruutu T, Wuorimaa T, Soininen A, et al.
Bone Marrow Transplant
. 1999 Sep;
24(6):671-8.
PMID: 10490735
In a randomized study, 20 adult allogeneic BMT recipients were vaccinated at 6 months and 22 at 18 months after BMT with Haemophilus influenzae type b (Hib)-diphtheria toxoid conjugate vaccine...
8.
Soininen A, Seppala I, Wuorimaa T, Kayhty H
Clin Diagn Lab Immunol
. 1998 Jul;
5(4):561-6.
PMID: 9665967
We describe standardization of an enzyme-linked immunosorbent assay (ELISA) for measuring immunoglobulin G1 (IgG1) and IgG2 concentrations of antibodies to pneumococcal capsular polysaccharide (Pnc PS). The ELISA uses a human...
9.
Lindsberg P, Ohman J, Lehto T, Karjalainen-Lindsberg M, Paetau A, Wuorimaa T, et al.
Ann Neurol
. 1996 Oct;
40(4):587-96.
PMID: 8871578
The central nervous system (CNS) is virtually isolated from circulating immunological factors such as complement (C), an important mediator of humoral immunity and inflammation. In circulation, C is constantly inhibited...